Consolidated Portfolio Review Corp Trims Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Consolidated Portfolio Review Corp lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 32.0% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 431 shares of the medical research company’s stock after selling 203 shares during the period. Consolidated Portfolio Review Corp’s holdings in Thermo Fisher Scientific were worth $229,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Coppell Advisory Solutions LLC purchased a new position in Thermo Fisher Scientific during the second quarter valued at approximately $33,000. Live Oak Investment Partners bought a new position in Thermo Fisher Scientific in the 4th quarter worth $36,000. Tyler Stone Wealth Management purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth $37,000. Indiana Trust & Investment Management CO purchased a new position in shares of Thermo Fisher Scientific in the third quarter valued at about $38,000. Finally, DHJJ Financial Advisors Ltd. purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $38,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Royal Bank of Canada increased their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Raymond James increased their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. TheStreet upgraded Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Finally, The Goldman Sachs Group increased their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $601.56.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $565.23 on Monday. The stock has a market cap of $215.75 billion, a price-to-earnings ratio of 36.58, a price-to-earnings-growth ratio of 2.38 and a beta of 0.80. The firm has a 50-day moving average of $571.66 and a two-hundred day moving average of $526.14. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period last year, the business posted $5.40 EPS. Thermo Fisher Scientific’s quarterly revenue was down 4.9% on a year-over-year basis. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be given a dividend of $0.39 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Insider Transactions at Thermo Fisher Scientific

In related news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Marc N. Casper sold 5,547 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $550.62, for a total value of $3,054,289.14. Following the sale, the chief executive officer now directly owns 43,608 shares in the company, valued at approximately $24,011,436.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,277 shares of company stock valued at $28,513,384. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.